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Abstract
Background: Fibroblast growth factor receptor 4 (FGFR4) displays multiple biological activities, including mitogenic
and angiogenic activity, and plays important roles in the etiology and progression of prostate cancer. Gly388Arg
polymorphism in FGFR4 gene has been reported to be involved in prostate cancer incidence and aggressiveness in
several studies. To derive a more precise estimation of the relationship, a meta-analysis was performed.
Methods: Odds ratios (ORs) with 95% confidence intervals (CIs) were estimated to assess the association.
Results: The Arg388 allele increased prostate cancer risk compared with Gly388 allele (OR = 1.17, 95% CI = 1.07-
1.29). When stratified by race, there was a significantly increased prostate cancer risk in Asian and Caucasian
populations. Moreover, prostate cancer patients with Arg/Arg genotype had a 1.34-fold increased risk of advanced
prostate cancer (95% CI: 1.03-1.74) compared with those with Gly/Gly+Gly/Arg genotype.
Conclusion: This meta-analysis showed the evidence that FGFR4 Gly388Arg polymorphism was associated with an
increased risk of prostate cancer development and progression, suggesting that FGFR4 Gly388Arg polymorphism
could be a marker for prostate cancer development and progression.
Background
Prostate cancer is the most frequently diagnosed solid
tumor and the second leading cause of cancer-related
death among American men, with an estimated 192,280
new cases and 27,360 deaths in the United States in
2009 [1]. The etiology of human prostate cancer is com-
plex and largely remains unknown.
Fibroblast growth factor receptor 4 (FGFR4) belongs
to the family of fibroblast growth factor receptors
(FGFR1-4), which display multiple biological activities,
including mitogenic and angiogenic activity, with a con-
sequent crucial role in cell differentiation, development,
hormonal and proliferative signaling in response to
more than 20 known ligands [2,3]. In light of its involve-
ment in the regulation of essential biologic mechanisms,
FGF signaling is also likely to play a role in tumor
growth and progression; indeed, dysreglation of this
pathway has been demonstrated in several tumor types
[3]. Recently, FGFR4 was found to be more abundantly
expressed in malignant than benign prostate cells and in
vitro suppression of FGFR4 expression effectively
blocked prostate cancer proliferation and invasion [4].
Moreover, strong expression of FGFR4 in prostate can-
cer cells, as assessed by immunohistochemistry, is signif-
icantly associated with increased clinical stage and
tumor grade and decreased patient survival [5].
A germ line polymorphism in FGFR4 gene, resulting in
different expression of FGFR4 containing either glycine
(Gly388) or arginine (Arg388) at codon 388 in the trans-
membrane domain of the receptor was identified several
years ago. In addition, the FGFR4 Arg388 allele may pre-
dispose cancer patients to disease progression, based on
the reported significant association between FGFR4 gen-
otype and tumor aggressiveness or patients’ survival in
several cancers [6,7].
To date, several studies had been reported to focus on
the association between this polymorphism and inci-
dence and aggressiveness of prostate cancer [4,8-12].
However, a single study may be too underpowered to
* Correspondence: mingchenseu@gmail.com
† Contributed equally
1Department of Urology, The Affiliated ZhongDa Hospital of Southeast
University, 87 Dingjia Bridge Hunan Road, Nanjing, 210009, China
Full list of author information is available at the end of the article
Xu et al. BMC Cancer 2011, 11:84
http://www.biomedcentral.com/1471-2407/11/84
© 2011 Xu et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
detect a possible small effect of the polymorphism on
prostate cancer, especially when the sample size is rela-
tively small. Hence, we carried out a meta-analysis of all
eligible case-control studies to derive a more precise
estimation of the association of FGFR4 Gly388Arg poly-
morphism with prostate cancer.
Methods
Publication search
PubMed and EMBASE were searched (the last search
update on the 1st Nov. 2010) using the search terms:
‘FGFR4 or fibroblast growth factor receptor 4’, ‘poly-
morphism’, ‘Gly388Arg or rs351855’ and ‘prostate cancer
or prostate neoplasm’. All published English language
papers with available full text matching the eligible cri-
teria were retrieved. In addition, we checked all the
references of relevant reviews and eligible articles that
our search retrieved. Two investigators (BX and SQC)
searched the literature and extracted data independently.
Inclusion, exclusion criteria and data abstraction
For inclusion in the meta-analysis, the identified articles
had to provide information on: (1) evaluation of FGFR4
Gly388Arg polymorphism and prostate cancer risk,
(2) using a case-control design and (3) containing infor-
mation about available genotype frequency that can help
infer the results in the papers. Major reasons for the
exclusion of studies were: (1) no control population;
(2) no usable data reported; (3) duplicates. For each of
the eligible case-control studies, the following data were
collected: the first author’s last name, year of publica-
tion, country of origin, ethnicity, numbers of genotyped
cases and controls, genotyping methods.
Statistical analysis
The strength of the association between the FGFR4
Gly388Arg polymorphism and prostate cancer risk was
measured by ORs with 95% confidence intervals (CIs).
We explored the association between allele Arg388 and
prostate cancer development and progression, as well as
homozygote comparison (Arg/Arg vs. Gly/Gly), domi-
nant genetic model [(Gly/Arg+Arg/Arg) vs. Gly/Gly]
and recessive model [Arg/Arg vs. (Gly/Gly+ Gly/Arg)].
Heterogeneity assumption was checked by a chi-square-
based Q-test [13]. A P-value of more than 0.05 for the
Q-test indicated a lack of heterogeneity among the
studies, so the summary OR estimate of each study
was calculated by the fixed-effects model (the Mantel-
Haenszel method). Otherwise, the random effects model
(DerSimonian and Laird method) was used [14,15]. The
significance of the pooled OR was determined by the
Z-test, and P < 0.05 was considered as statistically sig-
nificant. To evaluate the ethnic-specific effect, subgroup
analysis was conducted on the basis of different
ethnicities.
Evidence of publication bias was determined using
Begg’s [16] and Egger’s [17] formal statistical test and by
visual inspection of the funnel plot. All statistical ana-
lyses were performed with Stata software (version 10.0;




Using the searching terms, seven papers were reviewed
in the two online databases. The study of Spinola et al.
[18] was focused on the association between FGFR4
Gly388Arg polymorphism and lung cancer risk, and the
studies of Wang et al. [12] and Sahadevan et al. [4] were
not epidemiological association studies, so they were all
excluded in present study. In the four papers left, Fitz-
Gerald et al. [8] and Wang et al. [11] provided data on
both African-American and Caucasian. Overall, four
articles (six studies) with 2618 prostate cancer cases and
2305 controls were retrieved based on the search criteria
for prostate cancer susceptibility related to the FGFR4
Gly388Arg polymorphism. Study characteristics are
summarized in Table 1. All the studies used frequency-
matched controls to the cases by the age, sex or ethni-
city, and the distribution of genotypes in the controls
was consistent with Hardy-Weinberg equilibrium in all
studies. Moreover, among the four articles, three
[8,10,11] mentioned the association between FGFR4
Gly388Arg polymorphism and progression of prostate
cancer. The stratifications for pathological parameters
of the cases in the three articles were also shown in
Table 1. The cases of the three articles were all stratified
by Gleason score and tumor stage. However, the classifi-
cation standard of Gleason score was not uniform; thus,
we only focused on the association between FGFR4
Gly388Arg polymorphism and tumor stage (advanced vs.
localized). Advanced stage corresponded to T3 stage in
the study of Wang et al. [11], regional/distant stage in
the study of FitzGerald et al. [8], and stage C+D in the
study of Ma et al. [10], respectively. And localized stage
meant T2 stage in the study of Wang et al., local stage
in the study of FitzGerald et al., and stage A+B in the
study of Ma et al., respectively.
Quantitative synthesis
We observed a wide variation of Arg388 allele frequen-
cies across different ethnicities. The frequency of
Arg388 allele was 28.90% among Caucasian controls
and 41.57% among Asian controls, which were signifi-
cantly higher than that in African-American controls
(11.49%, P < 0.01).
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Overall, the combined result based on all studies
showed the evidence of an association between the
increased risk of prostate cancer and the variant geno-
types in different genetic models. As shown in Table 2
and Figure 1, the Arg388 allele increased overall prostate
cancer risk compared with Gly388 allele (OR = 1.17,
95% CI = 1.07-1.29). Significant main effects were also
observed in dominate genetic model (OR = 1.21, 95%
CI = 1.08-1.36).
When stratifying for race, results were similar. Spe-
cially, significantly increased risk was found among Cau-
casian populations (Arg388 and Gly388 comparison: OR =
1.21, 95% CI: 1.00-1.47; dominant genetic model: OR =
1.23, 95% CI: 1.08-1.40) and Asian population (Arg388
and Gly388 comparison: OR = 1.24, 95% CI: 1.02-1.51;
homozygote comparison: OR = 1.52, 95% CI: 1.05-2.22;
recessive genetic model: OR = 1.53, 95% CI: 1.10-2.14).
Although the effect in African-Americans was in the
same direction as for other groups, the difference
was not statistically significant (Arg388 and Gly388
comparison: OR = 1.15, 95% CI: 0.73-1.82; homozygote
comparison: OR = 2.17, 95% CI: 0.20-23.14; dominant
genetic model: OR = 1.11, 95% CI: 0.66-1.86 and reces-
sive genetic model: OR = 2.21, 95% CI: 0.18-26.83).
In addition, when concerning tumor stage and FGFR4
Gly388Arg polymorphism, patients with prostate cancer
with Arg/Arg genotype had a 1.34-fold increased risk of
advanced or metastatic prostate cancer (95% CI: 1.03-
1.74) compared with the Gly/Gly+Gly/Arg genotype
(seen Figure 2).
Sensitivity analysis
Sensitivity analysis was performed by sequential omis-
sion of individual studies. The pooled 95% CI for Arg388
vs. Gly388 was consistently over 1.0, indicating that the
results of this meta-analysis are stable.
Publication bias
Begg’s funnel plot and Egger’s test were performed to assess
the publication bias. The shape of the funnel plots seemed
Table 1 Main characteristics of selected studies
First
author




Wang 2004 Caucasian 284 97 125 117 42 53 40 4 Stratified by Gleason score (7-9 vs. 5-
6), pathological stage (T3 vs. T2),
lymph node metastasis (positive vs.




45 94 37 6 2 76 18 0
FitzGerald 2009 Caucasian 1254 1251 587 544 123 631 496 124 Stratified by Gleason score [≥7(4+3)




146 80 104 39 3 60 18 2
Ho 2009 Caucasian 397 439 183 182 32 235 167 37 -
Ma 2008 Asian 492 344 163 196 133 125 152 67 Stratified by tumor stage (stage D vs.
A+B+C) a, and Gleason score (8-10 vs.
2-7)
aStage A (T1a-bN0M0), StageB (T1c-2N0M0), Stage C (T3-4N0M0) and Stage D (T1-4N1M0-1 orT1-4N0-1M1) by the modified Whitmore-Jewett system.
Table 2 Stratified analyses of the FGFR4 Gly388Arg polymorphism on cancer risk
Variables na Cases/controls Arg vs. Gly Arg/Arg vs. Gly/Gly Gly/Arg+Arg/Arg vs. Gly/Gly Arg/Arg vs. Gly/Gly+ Gly/Arg
OR (95% CI) Pb OR (95% CI) Pb OR (95% CI) Pb OR (95% CI) Pb
Total 5 2618/2305 1.17 (1.07-1.29) 0.37 1.39 (0.97-1.99) 0.08 1.21 (1.08-1.36) 0.79 1.32 (0.90-1.94)c 0.03
Caucasian 3 1935/1787 1.21 (1.00-1.47) 0.09 1.40 (0.80-2.45)c 0.04 1.23 (1.08-1.40) 0.39 1.26 (0.72-2.19)c 0.04
African 2 191/174 1.15 (0.73-1.82) 0.95 2.17 (0.20-23.14) 0.17 1.11 (0.66-1.86) 0.62 2.21 (0.18-26.83) 0.15
Asian 1 492/344 1.24 (1.02-1.51) - 1.52 (1.05-2.22) - 1.15 (0.86-1.54) - 1.53 (1.10-2.14) -
Tumor stage
Localized 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
Advanced 1.18 (0.96-1.44) 0.75 1.33 (0.91-1.96) 0.89 1.01 (0.93-1.10) 0.44 1.34 (1.03-1.74) 0.61
aNumber of comparisons; bP value of Q-test for heterogeneity test; cRandom-effects model was used when P value for heterogeneity test < 0.05; otherwise, fixed-
effects model was used.
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symmetrical in the comparison of the Arg388 vs. Gly388
(Figure 3). Furthermore, Egger’s test was used to provide
statistical evidence for funnel plot symmetry (t = 1.30,
P = 0.26), suggesting that no publication bias was exist.
Discussion
The present meta-analysis, including 2,618 cases and
2,305 controls from six published studies, explored the
association between FGFR4 Gly388Arg polymorphism
and development and progression of prostate cancer. To
the best of our knowledge, this is the first meta-analysis
to explore FGFR4 Gly388Arg polymorphism in develop-
ment and progression of prostate cancer. The results
indicated that FGFR4 Arg388 allele is a potential risk
factor for developing and progressing prostate cancer.
These findings may be biologically plausible. The FGFR4
Gly388Arg polymorphism results in an amino acid
change in the transmembrane domain of the receptor,
which may alter the activity of the receptor. FGFR4 is
the activator of the MAPK signaling cascade, yet it is a
principal receptor for key mitogenic FGFs in prostate
cancer cells [19-21]. There was evidence that FGFR4
contributed to progression in liver, lung, colon tumors
[22] and prostate cancer [12]. The effects of FGFR4
Arg388 allele may also predispose cancer patients to
disease progression, based on the reported significant
association between FGFR4 genotype and tumor aggres-
siveness (lymph node involvement, advanced stage) or
patients’ survival [6,7], and the results about its biologi-
cal role on cancer cell motility and invasiveness [11]. In
our meta-analysis, we found that subjects carrying
Arg388 were associated with higher risk of developing
and progressing prostate cancer than those with
the wild-type allele, which confirmed the hypothesis
described above.
Some limitations of this meta-analysis should be
acknowledged. First of all, the control populations were
not uniform. Healthy populations as well as non-cancer
patients like BPH patients were included. Some indivi-
duals in the control group are likely to develop cancer
in subsequent years though they had no clinical symp-
toms at the time of investigation. Misclassification bias
results in deviation of genotype distribution in the con-
trols. Second, prostate cancer, as a complex disease, was
considered as the result of combined effects of multi-
factors, including inherited and environmental factors
[23], however, no such data was observed in previous
studies. Thus, our result was only based on unadjusted
estimates. Lacking of the information for the data analy-
sis may cause serious confounding bias. Third, the effect
Figure 1 Forest plot of prostate cancer risk associated with
FGFR4 Gly388Arg polymorphism (Arg allele vs. Gly allele). The
squares and horizontal lines correspond to the study-specific OR
and 95% CI. The area of the squares reflects the weight (inverse of
the variance). The diamond represents the summary OR and 95% CI.
Figure 2 Forest plot of prostate cancer progression associated
with FGFR4 Gly388Arg polymorphism (Arg/Arg vs. Gly/Gly+Gly/
Arg). The squares and horizontal lines correspond to the study-
specific OR and 95% CI. The area of the squares reflects the weight
(inverse of the variance). The diamond represents the summary OR
and 95% CI.
Figure 3 Begg’s funnel plot for publication bias test. Each point
represents a separate study for the indicated association. Log[OR],
natural logarithm of OR. Horizontal line, mean effect size.
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of the polymorphism was relatively trivial with small
ORs. We need further studies with larger number parti-
cipants to confirm the effect.
Our meta-analysis also had some advantages. First,
disease progression status as tumor stage was taken into
account in present study. Second, data in present study
were pooled from different studies, which significantly
increased statistical power of the analysis. Third, the
quality of studies included in our meta-analysis was
satisfactory and cruelly met our inclusion criterion.
Fourth, the distribution of genotypes in the controls was
consistent with Hardy-Weinberg equilibrium in all stu-
dies. We further performed sensitivity analysis to detect
the stability of the meta-analysis, and the results did not
alter the pattern of association and revealed that the risk
effect of Arg388 was stable. In addition, publication bias
was not detected in present study, indicating that our
findings seemed not to be due to biased publications.
Conclusions
Our meta-analysis showed the evidence that FGFR4
Arg388 allele was associated with an increased risk of
prostate cancer development and progression, suggest-
ing that FGFR4 Gly388Arg polymorphism could be a
marker for prostate cancer development and progres-
sion. Based on the limitations of present study list
above, further prospective researches using standardized
unbiased methods, and larger numbers of worldwide
participants are expected to examine the association to
confirm our results, and other possible confounding risk
factors like age, life style, and familial history should
also be controlled when it was assessed. Moreover,
gene-gene and gene-environment interactions should
also be considered.
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